Group Chief Financial Officer — Precision-Oncology Portfolio

The mandate

A recent operating review made clear that success depends on rebuilding capital allocation, performance truth and external confidence in a privately held venture- or institutionally-backed biotechnology company. The immediate business arena is the precision-oncology portfolio, where a platform-versus-asset choice has exposed choices that can no longer be deferred. The successful executive will inherit an organisation with real strengths, but also competing stakeholder expectations and investment cases that require firmer evidence.

The accountable perimeter is approximately USD 1,200 million across the biotechnology value chain. It includes several customer, product or delivery clusters and roughly 200 employees and material partners. These are deliberately rounded, composite ranges: they establish candidate scale without encoding a recognisable client footprint.

The board wants a Group Chief Financial Officer who can reduce a long list of activity to a small set of consequential choices. The seat must deliver a platform-versus-asset choice while protecting the capabilities that make the precision-oncology portfolio valuable. Authority will cover resources, leadership appointments and operating standards within scope; enterprise trade-offs will go directly to the board sponsor.

The first year must finish with forecast integrity, investment discipline and durable funding headroom. Success will require direct engagement with customers, employees, capital providers, regulators where relevant and critical partners across the United States. This is an operating mandate with board access, not a staff role that stops at recommendations.

Why this seat is open

This is a newly created Group Chief Financial Officer — Precision-Oncology Portfolio seat, established because a platform-versus-asset choice now requires one accountable executive rather than distributed ownership. The board has classified the appointment as urgent and intends to move from qualified shortlist to offer within 6–8 weeks. Interim governance protects the precision-oncology portfolio, but it is not a substitute for a permanent appointee. The external search remains confidential to avoid unnecessary disruption before the appointment is agreed.

What you will own

• Set the value thesis for the precision-oncology portfolio, translate it into no more than five priorities and stop activity that cannot support those priorities with evidence.
• Carry stewardship of approximately USD 1,200 million, including allocation, risk acceptance, forecast integrity and the quality of decisions taken at the operating review.
• Lead a perimeter of about 200 employees and partners, appointing a team with explicit decision rights and credible succession for every critical seat.
• Resolve a platform-versus-asset choice through named owners, dated milestones and escalation thresholds that make variance visible before a quarter or programme gate closes.
• Install one review linking commercial, customer, financial, people, technology and risk outcomes; eliminate reconciliations that disguise accountability.
• Sponsor the two or three capability investments that can materially change the trajectory, and close initiatives whose evidence does not justify continued funding.
• Build a three-year talent and succession plan for the precision-oncology portfolio, reducing dependence on individual executives and creating mobility across the wider Biotechnology group.

The first 12 months

• Days 1–90: Validate the baseline; meet the 30 stakeholders most consequential to the precision-oncology portfolio; assess the leadership team; stabilise immediate customer, people and control risks; and agree a board-owned scorecard.
• Months 4–9: Make the principal portfolio and organisation choices, fill critical leadership gaps, install the new cadence and deliver the first measurable release of cash, capacity, customer value or controlled risk.
• Months 10–12: Establish a repeatable performance trend, secure the following year’s capital and talent plan, prove that fixes are sustained and present a three-year value case with downside actions.

What the board will measure

• Delivery of the agreed first-year value case within a 10% tolerance, with variance surfaced before the relevant reporting period closes.
• A decision-useful forecast across three consecutive quarters that reconciles operating, cash, customer and people assumptions.
• Closure of the highest-priority issues behind a platform-versus-asset choice by their board-approved dates, with independent evidence that remediation is sustained.
• Retention of at least 90% of identified critical talent and ready-now successors for at least 70% of the Group Chief Financial Officer’s direct reports.
• A quantified improvement in the primary precision-oncology portfolio constraint, supported by a clean baseline, named data owner and repeatable measurement method.
• No unresolved high-severity escalation older than 30 days and no material surprise withheld from the agreed governance forum.

The person

You are currently a Group CFO, listed-company CFO or major Divisional CFO in a privately held organisation. Your track record includes a transition where the original plan ceased to be sufficient and you can explain the choices you personally made, the evidence used and the numerical impact. Candidates from biotechnology, pharmaceuticals, diagnostics, research tools or computational biology will be considered where the operating model, customer stakes and governance intensity are comparable.

You bring 28+ years of progressive experience, consistent with the 28-plus band. At minimum, you have carried a P&L, book, budget or accountable portfolio of USD 750 million and led at least 180 employees. Advisory candidates must show equivalent client-value ownership and multi-disciplinary leadership rather than subject expertise alone.

The board expects two completed transitions: one involving a difficult portfolio or resource choice, and another requiring the leadership system to change during material pressure. You should be equally comfortable challenging an optimistic case and creating followership after the decision. References must distinguish your contribution from the institution around you.

An undergraduate degree or equivalent professional formation is required; a relevant postgraduate or regulated professional qualification is advantageous where the mandate warrants it. The role is based in San Diego, United States. Relocation is expected; a structured commute may be considered only during an agreed transition period. Regional and intercontinental travel is part of the appointment, but the seat is not remote.

Non-negotiables

• Current or recent accountability at the level of Group CFO, listed-company CFO or major Divisional CFO, with direct exposure to a board, investment committee or equivalent enterprise-governance forum.
• Proven ownership of at least USD 750 million and leadership of no fewer than 180 employees in a comparable operating context.
• One completed example of rebuilding capital allocation, performance truth and external confidence, with outcomes sustained for at least two reporting periods after the intervention.
• Sector credibility from biotechnology, pharmaceuticals, diagnostics, research tools or computational biology; purely functional experience without operating consequences will not meet the bar.
• Willingness to meet the San Diego location expectation, complete conflicts and background diligence, and protect the search’s confidentiality.

Compensation and terms

The anticipated package is USD 500,000–750,000 base + annual incentive and long-term participation, calibrated to final scope and the candidate’s current mix. Long-term participation follows the employer’s normal vesting and performance conditions. This is a full-time executive appointment with a standard five-day working week, additional availability appropriate to the office and material travel during diagnosis and implementation. A notice period of up to 6 months can be accommodated. No application, assessment, placement or onboarding fee is charged to candidates.

How to apply

The complete mandate is publicly readable on its canonical job page. Apply through /jobs/cfo-precision-oncology-portfolio-san-diego-bt02/apply before 18 October 2026 at 23:59 UTC. The application route may require one account sign-in, so structured data must state directApply: false. Applicants submit their own profile; no payment is required. If the vacancy closes early, the page owner must close applications and remove or expire its JobPosting markup immediately.

Confidentiality

The employer is represented as confidential, which Google permits for anonymous recruitment. Identifying information will be shared only after mutual relevance is established and an undertaking is in place. Rounded scale, blended context and broad archetypes are intentional and must not be used to infer a company name.